BridgeBio Oncology Therapeutics (NASDAQ:BBOT) Now Covered by Oppenheimer

Stock analysts at Oppenheimer started coverage on shares of BridgeBio Oncology Therapeutics (NASDAQ:BBOT) in a research report issued to clients and investors on Monday. The brokerage set an “outperform” rating and a $22.00 price target on the stock. Oppenheimer’s target price suggests a potential upside of 177.95% from the stock’s current price.

A number of other equities research analysts have also recently weighed in on the company. HC Wainwright increased their price target on BridgeBio Oncology Therapeutics from $27.00 to $29.00 and gave the company a “buy” rating in a research note on Friday, March 6th. Wall Street Zen downgraded shares of BridgeBio Oncology Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, May 16th. Canaccord Genuity Group started coverage on shares of BridgeBio Oncology Therapeutics in a research report on Monday, May 11th. They issued a “buy” rating and a $23.00 price objective on the stock. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of BridgeBio Oncology Therapeutics in a research note on Thursday. Five equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $24.25.

BridgeBio Oncology Therapeutics Trading Up 4.7%

BridgeBio Oncology Therapeutics stock traded up $0.35 during midday trading on Monday, reaching $7.92. 29,664 shares of the company’s stock were exchanged, compared to its average volume of 354,424. The firm has a 50-day moving average price of $8.39. The company has a market cap of $634.07 million, a price-to-earnings ratio of -3.82 and a beta of 0.29. BridgeBio Oncology Therapeutics has a 52 week low of $7.00 and a 52 week high of $14.87.

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($526.11) earnings per share (EPS) for the quarter. On average, sell-side analysts expect that BridgeBio Oncology Therapeutics will post -2.32 earnings per share for the current year.

Institutional Trading of BridgeBio Oncology Therapeutics

Several institutional investors have recently added to or reduced their stakes in the company. Paradigm Biocapital Advisors LP increased its position in BridgeBio Oncology Therapeutics by 21.2% during the 4th quarter. Paradigm Biocapital Advisors LP now owns 2,261,749 shares of the company’s stock worth $28,317,000 after buying an additional 395,608 shares during the period. Laurion Capital Management LP boosted its position in shares of BridgeBio Oncology Therapeutics by 40.1% in the fourth quarter. Laurion Capital Management LP now owns 1,464,938 shares of the company’s stock valued at $18,341,000 after acquiring an additional 419,138 shares during the period. Armistice Capital LLC boosted its position in shares of BridgeBio Oncology Therapeutics by 142.7% in the fourth quarter. Armistice Capital LLC now owns 1,000,000 shares of the company’s stock valued at $12,520,000 after acquiring an additional 588,000 shares during the period. Geode Capital Management LLC grew its stake in shares of BridgeBio Oncology Therapeutics by 3.8% in the fourth quarter. Geode Capital Management LLC now owns 561,987 shares of the company’s stock valued at $7,039,000 after acquiring an additional 20,385 shares in the last quarter. Finally, Catalio Capital Management LP acquired a new position in shares of BridgeBio Oncology Therapeutics in the fourth quarter valued at about $5,142,000. 54.89% of the stock is currently owned by institutional investors.

BridgeBio Oncology Therapeutics Company Profile

BridgeBio Oncology Therapeutics (NASDAQ:BBOT) is a publicly traded biotechnology company focused on discovering and developing therapies for cancer. The company concentrates on translating scientific insights into clinical-stage programs aimed at addressing oncology indications with unmet medical need.

BridgeBio Oncology’s activities center on research and development of investigational therapeutics, advancing drug candidates through preclinical studies and clinical trials. Its work typically involves in-house discovery efforts and collaborations with academic and industry partners to identify targets, optimize compounds, and generate the clinical data needed to support regulatory development.

Public information about BridgeBio Oncology Therapeutics’ specific programs, geographic operations and leadership is limited in the sources available here.